PSTV (Plus Therapeutics) Selling, General, & Admin. Expense: $14.58 Mil (TTM As of Mar. 2026)


PSTV Plus Therapeutics Inc PSTV
28 GF Score
Price $4.30
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Selling, General, & Admin. Expense?

Plus Therapeutics PSTV +7.50% 28 Selling, General, & Admin. Expense is $14.58 Mil as of Mar. 2026. GuruFocus rates PSTV with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Plus Therapeutics's selling, general, & admin. expense for the three months ended in Mar. 2026 was $5.28 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was $14.58 Mil.


Plus Therapeutics  (NAS:PSTV) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Plus Therapeutics Selling, General, & Admin. Expense Related Terms


Plus Therapeutics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Plus Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plus Therapeutics Selling, General, & Admin. Expense Chart

Plus Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.85 10.24 8.54 9.94 12.13

Plus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.84 1.68 3.44 4.17 5.28

PSTV vs KYNB, VTGN, TVGN: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Plus Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plus Therapeutics Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Selling, General, & Admin. Expense falls into.


PSTV
28GF Score
Plus Therapeutics Inc PSTV
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Plus Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $14.58 Mil mean?
Plus Therapeutics (PSTV) has a Selling, General, & Admin. Expense of $14.58 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Plus Therapeutics and its competitors.
Is Plus Therapeutics' Selling, General, & Admin. Expense too high?
Plus Therapeutics' current Selling, General, & Admin. Expense is $14.58 Mil. Overall, Plus Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Selling, General, & Admin. Expense compare to KYNB and VTGN?
Plus Therapeutics' Selling, General, & Admin. Expense of $14.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Plus Therapeutics and its competitors. Plus Therapeutics's current Selling, General, & Admin. Expense is $14.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current Selling, General, & Admin. Expense of $14.58 Mil. The current Selling, General, & Admin. Expense is $14.58 Mil. Plus Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current Selling, General, & Admin. Expense is $14.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges XMP1:Germany
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
28GF Score

Get the complete analysis for PSTV

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.30
Price